Rigel Provides Update on FDA Review of Fostamatinib for ITP

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that during the company ' s mid-cycle meeting with the U.S. Food and Drug Administration (FDA) the FDA indicated that, at this point,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news